A prospective, observational study for outcomes and safety profiles of MRI-guided transurethral ultrasound ablation of the prostate for prostate cancer

A prospective, observational study for outcomes and safety profiles of MRI-guided transurethral ultrasound ablation of the prostate for prostate cancer - TULSAPROS study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038291

Enrollment

100

Registered

2019-10-15

Start date

2019-10-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Localized prostate cancer T stage: T1, all T2 and T3a

Exclusion criteria

Exclusion criteria: Patients contraindicated for MRI (patients with intracorporeal metal incompatible with MRI) Patients without histopathological diagnosis of prostate cancer

Design outcomes

Primary

Measure	Time frame
Recurrence of prostate cancer until 5 years after the treatment	—

Secondary

Measure	Time frame
PSA value, MRI findings, prostate volume, lower urinary tract symptom, sexual function and quality of life evaluation using following questionnaires (IPSS, OABSS, EPIC, SF-12), voiding function using urodynamic studies, required managements for voiding function, adverse events (urinary incontinence, erectile dysfunction, urethral stricture, urinary tract infection, rectal injury, hematuria, voiding dysfunction, urinary retention, others), learning curve of treatment workflow.	—

Measure

Time frame

PSA value, MRI findings, prostate volume, lower urinary tract symptom, sexual function and quality of life evaluation using following questionnaires (IPSS, OABSS, EPIC, SF-12), voiding function using urodynamic studies, required managements for voiding function, adverse events (urinary incontinence, erectile dysfunction, urethral stricture, urinary tract infection, rectal injury, hematuria, voiding dysfunction, urinary retention, others), learning curve of treatment workflow.

—

Countries

Japan

Contacts

Public ContactMasayoshi Miura

Sapporo Hokuyu Hospital Department of Urology and Renal Transplant Surgery

uromasa@mac.com011-865-0111

Outcome results